Heterogeneity of kinase inhibitor resistance mechanisms in GIST
暂无分享,去创建一个
J. Fletcher | G. Demetri | M. Heinrich | C. Corless | C. Fletcher | Meijun Zhu | C. Fletcher | I. Kepten | B. Liegl | M. Zhu | C. Corless | G. Demetri | C. Le | MC Heinrich | J. Fletcher | M. Heinrich | Claudia Le
[1] J. Fletcher,et al. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway , 2007, Oncogene.
[2] J. Fletcher,et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. , 2007, Cancer research.
[3] M. Bertagnolli,et al. Mechanisms of sunitinib malate (SU) resistance in gastrointestinal stromal tumors (GISTs) , 2007 .
[4] P. Casali,et al. c-Kit/PDGFRA Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal Tumors , 2007, Clinical Cancer Research.
[5] Narasimhan P. Agaram,et al. Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors , 2007, Clinical Cancer Research.
[6] C. Antonescu,et al. The Activity of Sunitinib against Gastrointestinal Stromal Tumor Seems to be Distinct from Its Antiangiogenic Effects , 2006, Clinical Cancer Research.
[7] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[8] J. Fletcher,et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Fletcher,et al. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. , 2006, Cancer research.
[10] P. Marynen,et al. Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate , 2006, Clinical Cancer Research.
[11] E. Wardelmann,et al. Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate , 2006, Clinical Cancer Research.
[12] Narasimhan P. Agaram,et al. Comparative Ultrastructural Analysis and KIT/PDGFRA Genotype in 125 Gastrointestinal Stromal Tumors , 2006, Ultrastructural pathology.
[13] M. Heinrich,et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Elisa Rossi,et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. van Glabbeke,et al. RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. , 2005, European journal of cancer.
[16] C. Antonescu,et al. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.
[17] P. Marynen,et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.
[18] Rossella Bertulli,et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.
[19] M. van Glabbeke,et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. , 2004, European journal of cancer.
[20] D. Hallahan,et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels , 2004, Angiogenesis.
[21] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Gerald McMahon,et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. , 2003, Cancer research.
[23] N. Pryer,et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. , 2003, Molecular cancer therapeutics.
[24] M. Heinrich,et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.
[25] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[26] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[28] M. Heinrich,et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. , 2002, The American journal of pathology.
[29] B. Druker,et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] C. Fletcher,et al. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. , 2002, American journal of clinical pathology.
[31] C. J. Chen,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.
[32] S Torihashi,et al. Blockade of kit signaling induces transdifferentiation of interstitial cells of cajal to a smooth muscle phenotype. , 1999, Gastroenterology.
[33] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.